Rosopatamab
Rosopatamab Basic information
- Product Name:
- Rosopatamab
- Synonyms:
-
- Rosopatamab
- Research Grade Rosopatamab(DHG01304)
- Research Grade Rosopatamab
- Rosopatamab (anti-PSMA)
- CAS:
- 2260767-49-3
- MW:
- 0
- Mol File:
- Mol File
Rosopatamab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Rosopatamab Usage And Synthesis
Uses
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency[1].
in vivo
Combination of 177Lu-DOTA-rosopatamab (6 MBq, i.v., single) and Peposertib (HY-101570) achieves a 3 of 4 complete response rate in a LNCaP prostate cancer mice model[2].
177Lu-rosopatamab (anti-PSMA) (6 MBq, i.v., single) plus Peposertib (HY-101570) has 75% complete response (3/4) vs 25% complete response (1/4) in the 177Lu-anti-PSMA (6MBq) alone arm in the prostate BALB/c nude mice model[3].
IC 50
RDC Antibody
References
[1] Antonini P, et al. 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT)[J]. 2022.
[2] Johnstone CN, et al. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. J Nucl Med. 2025 Jan 30:jnumed.124.268695. DOI:10.2967/jnumed.124.268695
[3] Johnstone C, et al. Addition of DNA dependent protein kinase (DNA-PK) inhibitor peposertib enhances efficacy of 177Lu-based radioimmunotherapy in pre-clinical models of prostate and renal cell carcinoma. 2023.
RosopatamabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com